Table 2 PD-L1/PD-1 studies with reported outcome in GBC
From: Overview of current targeted therapy in gallbladder cancer
Clinical trail number | Study phase | Treatment agent | Checkpoint target | Number of patients | Outcome | Ref. |
|---|---|---|---|---|---|---|
NCT02443324 | I | Pembrolizumab + ramucirumab | PD-1 + VEGFR | 26 | PR: 3.8%, mPFS: 1.64 months, mOS: 6.4 months | |
JapicCTI-153098 | I | Nivolumab | PD-1 | 34 (33% GBC) | PR: 37%, mPFS: 4.2 months, mOS: 15.4 months | |
Nivolumab with chemotherapy | 30 (33% GBC patients) | PR: 3%, mPFS: 1.4 months, mOS: 5.2 months | ||||
NCT02829918 | II | Nivolumab | PD-1 | 54 (26% GBC) | PR: 22%, DCR: 60%, mPFS: 4 months, mOS: 14.2 months | |
NCT02054806 | I | Pembrolizumab | PD-1 | 24 (membranous PD-L1 ≥1%) | PR: 13%, SD: 17%, mPFS: 1.8 months, mOS: 6.2 months | |
NCT02628067 | II | Pembrolizumab | PD-1 | 104 | PR: 5.8%, mPFS: 2 months, mOS: 7.4 months | |
NCT01938612 | II | Duvalumab with/without tremelimumab | PD-L1 | 42 (45% GBC) | PR: 48%, mPFS: 1.5 months, mOS: 8.1 months | |
|  | PD-L1 + CTLA-4 | 65 (25% GBC) | PR: 11%, mPFS: 1.6 months, mOS: 10.1 months | |||
NCT01853618 | I | Tremelimumab + RFA | PD-L1 + CTLA-4 | 20 (10% GBC) | PR: 12.5%, mPFS: 3.4 months, mOS: 6 months | |
NCT02699515 | I | M7824 | PD-L + TGF-β | 30 (40% GBC) | ORR: 20%, mOS: 12.7 months |
